文献速递肾移植水电解质与酸碱

Plasma-Lyte-148与标准静脉液体在儿童肾移植中的随机对照试验

A pragmatic, open-label, randomized controlled trial of Plasma-Lyte-148 versus standard intravenous fluids in children receiving kidney transplants (PLUTO).
PubMed 文献 · Kidney Int · 2023-10-31

这项实用、开放标签的随机对照试验将儿童肾移植受者按1:1分配至Plasma-Lyte-148组或标准围手术期静脉液体组,比较移植后72小时内临床显著电解质和酸碱异常。Plasma-Lyte-148组高钠血症更常见,但液体处方变更更少,高氯血症、酸中毒和低镁血症更少。

要点

  • Plasma-Lyte-148未改变儿童肾移植后急性低钠血症的发生比例。
  • Plasma-Lyte-148组高钠血症更常见,但液体处方变更、高氯血症、酸中毒和低镁血症更少。
  • 严重不良事件发生率在Plasma-Lyte-148组为9%,标准液体组为7%。

核心结论

  • 围手术期使用Plasma-Lyte-148与标准液体相比,未改变儿童肾移植后急性低钠血症的发生比例,但液体处方变更更少,高氯血症和酸中毒更少见。

研究设计与样本

  • 实用、开放标签、随机对照试验,将儿童肾移植受者按1:1随机分配至Plasma-Lyte-148组(68例)或标准治疗围手术期静脉液体组(69例),标准液体主要为0.45%氯化钠和0.9%氯化钠溶液。

主要发现

  • 其余次要结局在两组间无差异;严重不良事件在Plasma-Lyte-148组报告9%,标准液体组报告7%。

临床怎么用

  • 儿童肾移植围手术期使用Plasma-Lyte-148可减少液体处方变更、高氯血症和酸中毒,但需注意高钠血症更常见。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute electrolyte and acid-base imbalance is experienced by many children following kidney transplant. This is partly because doctors give very large volumes of artificial fluids to keep the new kidney working. When severe, fluid imbalance can lead to seizures, cerebral edema and death. In this pragmatic, open-label, randomized controlled trial, we randomly assigned (1:1) pediatric kidney transplant recipients to Plasma-Lyte-148 or standard of care perioperative intravenous fluids (predominantly 0.45% sodium chloride and 0.9% sodium chloride solutions). We then compared clinically significant electrolyte and acid-base abnormalities in the first 72 hours post-transplant. The primary outcome, acute hyponatremia, was experienced by 53% of 68 participants in the Plasma-Lyte-148 group and 58% of 69 participants in the standard fluids group (odds ratio 0·77 (0·34 - 1·75)). Five of 16 secondary outcomes differed with Plasma-Lyte-148: hypernatremia was significantly more frequent (odds ratio 3·5 (1·1 - 10·8)), significantly fewer changes to fluid prescriptions were made (rate ratio 0·52 (0·40-0·67)), and significantly fewer participants experienced hyperchloremia (odds ratio 0·17 (0·07 - 0·40)), acidosis (odds ratio 0·09 (0·04 - 0·22)) and hypomagnesemia (odds ratio 0·21 (0·08 - 0·50)). No other secondary outcomes differed between groups. Serious adverse events were reported in 9% of participants randomized to Plasma-Lyte-148 and 7% of participants randomized to standard fluids. Thus, perioperative Plasma-Lyte-148 did not change the proportion of children who experienced acute hyponatremia compared to standard fluids. However fewer fluid prescription changes were made with Plasma-Lyte-148, while hyperchloremia and acidosis were less common.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Hayes WN, Laing E, Brown R, et al. A pragmatic, open-label, randomized controlled trial of Plasma-Lyte-148 versus standard intravenous fluids in children receiving kidney transplants (PLUTO). Kidney Int. 2023. PMID: 37914088. doi:10.1016/j.kint.2023.09.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。